FilingReader Intelligence
Hengrui Medicine net profit surges 36.9% in Q1 2025
April 24, 2025 at 05:22 PM UTC•By FilingReader AI
Jiangsu Hengrui Medicine (SSE:600276) announced its first-quarter results for 2025, showcasing significant growth in key financial metrics. Net profit attributable to shareholders surged by 36.9% year-over-year to CNY 1.874 billion, compared to CNY 1.369 billion in the same period last year. Revenue also saw a healthy increase of 20.14%, reaching CNY 7.206 billion.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
News Alerts
Get instant email alerts when Jiangsu Hengrui Medicine publishes news
Free account required • Unsubscribe anytime